PRA International, a Clinical Research Organization, announced today the appointment of Dr. Jerome Wilson as Senior Medical Director of Late Phase Services.
JEROME WILSON JOINS PRA INTERNATIONAL’S LATE PHASE SERVICE GROUP
Dr. Jerome Wilson to serve as Lead Epidemiologist
October 27, 2008, Raleigh, N.C. - PRA International, a leading Clinical Research Organization, announced today the appointment of Dr. Jerome Wilson as Senior Medical Director of Late Phase Services. As the Lead Epidemiologist, Dr. Wilson is responsible for providing consulting services and developing post-marketing strategies for PRA clients.
PRA provides extensive Phase IV Post-Marketing services to pharmaceutical and biotech companies. The company has executed more than 150 Late Phase studies in 23 countries, recruiting over 126,000 patients in nearly 12,000 sites.
In addition to more than 15 years of scientific management experience in the pharmaceutical industry, Dr. Wilson served as Senior Interdisciplinary Scientist and Team Leader for Anthrax Therapeutics at the U.S. Department of Health and Human Services (HHS). For this role, the Biomedical Advanced Research and Development Authority Office recognized Dr. Wilson for distinguished service. Dr. Wilson also served as Associate Director for Scientific Program Operations at the National Center on Minority Health and Health Disparities at the National Institutes of Health (NIH). He received the NIH Director’s Award for his work on the Genome Wide Association Studies Policy Development Team.
Additionally, Dr. Wilson served as Senior Director/Team Leader of Outcomes Research at Pfizer and has held appointments at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute’s Division of Cancer Epidemiology and Genetics, Howard University's Cancer Center, and Georgetown University's School of Medicine.
“We are pleased to add Dr. Wilson to our Late Phase Services team”, commented Maria Harrison, Vice President of PRA Late Phase Services. “His expertise in the post-marketing field will serve as a tremendous benefit to our clients, and our team.” Dr. Wilson holds an A.B. Cum Laude from Dillard University, an A.M. from Harvard Medical School, and a Ph.D. from the University Of North Carolina School Of Public Health.
About PRA International
PRA International is a privately held, global Clinical Research Organization providing services through all phases of clinical development. We specialize in Oncology, CNS, respiratory/allergy diseases, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials in more than 60 countries on six continents through our global offices. PRA’s therapeutic expertise, global reach, and project experience with local knowledge enable our project teams to deliver consistent, timely, and reliable service for our clients. PRA's Late Phase Services group supports global and regional post-approval studies with management in North America and Europe.
To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.